The Second Affiliated Hospital of Soochow University
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Chunfeng
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Recruiting
2
300
RoW
LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
04/25
07/25
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders

Recruiting
2
162
RoW
BAT4406F Injection, BAT4406F Placebos
Bio-Thera Solutions
Optic Neuromyelitis Spectrum Disease
05/25
05/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Chunfeng
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Recruiting
2
300
RoW
LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
04/25
07/25
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders

Recruiting
2
162
RoW
BAT4406F Injection, BAT4406F Placebos
Bio-Thera Solutions
Optic Neuromyelitis Spectrum Disease
05/25
05/26

Download Options